Global Antibiotic Research and Development Partnership, North America (GARDP NA) seeks an Executive Director to build the presence and profile of GARDP NA’s mission and objectives throughout the United States and Canada
A baby, just two days old, is diagnosed with a life-threatening bloodstream infection. A mother of two undergoing treatment for breast cancer gets pneumonia. An elderly man acquires a joint infection after undergoing a hip replacement.
These three scenarios could take place anywhere in the world. What they all have in common is the need for effective antibiotics – fast. The rapid development of antibiotic resistance means that new drugs are urgently needed. However, most large pharmaceutical companies have abandoned the research and development of antibiotics.
GARDP North America addresses antibiotic resistance as one of the biggest threats to health in North America and globally. Nearly 1.3 million people die globally every year from drug-resistant infections, and 4.6 billion dollars are lost each year due to drug-resistant infections in the US alone. Policymakers and legislators in the US have recognized the urgency of this issue by providing funding for early-stage antibiotic development, as well through pending legislation to provide support for market introduction and access. GARDP NA works to accelerate development of and access to antibiotics for adults and children in the US and globally.
GARDP NA was established in 2021 as a partner of the GARDP Foundation with the objective of addressing antimicrobial resistance in North America and worldwide. The GARDP Foundation is a Swiss not-for-profit organization, based in Geneva and established in 2016 by the World Health Organization and the Drugs for Neglected Diseases Initiative to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. GARDP NA operates independently with its own governing Board and has filed for IRS 501(c)(3) status within the United States. The GARDP Foundation is supporting GARDP NA as the organization becomes established in North America. GARDP NA has the long-term goal of strengthening the identity and visibility of GARDP’s mission, and the short-term goals of ensuring that GARDP NA is driving actions to reduce antibiotic resistance and develop new antibiotics in the US.
GARDP Programs
GARDP NA and the GARDP Foundation focus on four programs to address drug resistance:
Serious Bacterial Infections
Serious bacterial infections are among the leading cause of death for people in hospitals. Antibiotic resistance is making these infections increasingly difficult to treat. GARDP is working on treatments for these infections, prioritizing those caused by the bacteria with the greatest increases in antibiotic resistance.
Sexually Transmitted Infections
Infection rates of gonorrhea are increasing, with 82 million new cases each year worldwide. This infection—which can lead to infertility, ectopic pregnancy, and increased risk of HIV transmission—has progressively developed resistance to available treatments. GARDP is supporting late-stage trial of a new treatment for gonorrhea.
Antibiotics for Children
Every year 3 million babies and 1.2 million children suffer from sepsis, a life-threatening complication of infection. 3 out of every 10 neonatal sepsis deaths result from drug-resistant bacteria. The GARDP Foundation has recently announced results from a major international study to inform the development of improved antibiotic treatment regimens for neonatal sepsis. This study has shown that antibiotic resistance is now one of the major threats to newborn health globally. This is a major problem for babies in all countries, both rich and poor.
Discovery and Research
GARDP’s discovery and exploratory program focuses on three activities to advance antibiotic R&D: discovery and exploratory research; asset evaluation and development; and scientific affairs and REVIVE.
GARDP’s discovery and exploratory program focuses on three activities to advance antibiotic R&D: discovery and exploratory research; asset evaluation and development; and scientific affairs and REVIVE.
This program focuses on discovery and exploratory research, asset evaluation and development, and scientific affairs to advance antibiotic research and development. This program includes REVIVE, an education and collaboration program to improve, accelerate, and streamline drug discovery and research and development by directly connecting researchers with established and retired antibiotic researchers and developers, and by facilitating learning and knowledge exchange.
The GARDP Foundation was established in 2016 by the World Health Organization (WHO) and Drugs for Neglected Diseases initiative (DNDi) to deliver on the Global Action Plan on Antimicrobial Resistance. After six years in operation, the GARDP Foundation has built a pipeline to advance the programs discussed above. The GARDP Foundation has formed over 60 partnerships in 22 countries that span governments, the biomedical and pharmaceutical industries, research institutions, nonprofits, and civil society.
GARDP bridges the gap between innovation and access by focusing on developing therapeutic candidates in late-stage clinical development. This requires identifying the barriers to access and finding innovative ways to overcome them. GARDP also explores ways to ensure there is a viable market and sustainable supply of treatments in the long-term. To tackle the growing antibiotic resistance crisis, GARDP has set the 5 BY 25 goal, which seeks to deliver five new treatments by 2025 for drug-resistant infections that pose the greatest threat to health and economic security.
![]() |
![]() |
The Executive Director for GARDP North America will build the presence and profile of GARDP’s mission and objectives in the United States and Canada. They are responsible for managing the operations of GARDP North America and implementing a fundraising and visibility strategy to secure funding partnerships from both public sources (government agencies and US-based multilateral institutions) and private sources (foundations, corporations, and major donors).
The new Executive Director will be a visionary, able to develop and execute strategy. They will engage in US policy activities as they relate to antibiotic development and antibiotic resistance and maintain relationships with funders (public and private), industry, policy makers, and multilateral organizations to support the mission of GARDP NA and the GARDP Foundation. The new Executive Director will collaborate with the GARDP Foundation in Geneva and other regional offices with the common purpose of raising awareness and developing solutions to combat antibiotic resistance worldwide. The GARDP NA Board will support the new Executive Director and will be a resource for establishing GARDP NA within the United States. The new Executive Director will take full advantage of all that the GARDP NA Board has to offer.
In the first six months, the Executive Director will be responsible for conducting a comprehensive assessment of the organization and presenting recommendations for new goal setting and achievement.
Strategic Leadership
External Affairs
Operations
All qualified candidates will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, veteran status, or any other characteristic protected by law.
Please email your cover letter and resume in confidence to: gardpna@developmentguild.com
Suzanne Battit
Senior Vice President
Development Guild DDI